8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 6, 2026·SEC
CorMedix Inc.(CRMD)Earnings, Financials & Key Ratios
CRMD•NASDAQ
$8.87
4.3× P/E·Price updated Jul 7, 2026
AboutCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Show more
- Revenue$312M+617.0%
- EBITDA$165M+849.0%
- Net Income$163M+1009.4%
- EPS (Diluted)2.04+780.0%
- Gross Margin88.46%-4.5%
- EBITDA Margin52.98%+204.5%
- Operating Margin48.17%+193.7%
- Net Margin52.31%+226.8%
- ROE66.56%+387.3%
CRMD Price & Volume
CorMedix Inc. (CRMD) stock price & volume — 10-year historical chart
Loading chart...
DefenCath Commercial Scaling Drives Robust Profitability Gains
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Decelerating
Profitability:Strong
Financial:Healthy
Cash Flow:Improving
Primary Risk:Reimbursement cliff and adoption
Key Thesis Takeaways
- CorMedix has successfully transitioned into a commercial-stage entity, evidenced by its ability to scale operating income to $63.7M in 2026Q1.
- While the company benefits from high gross margins exceeding 80%, long-term sustainability remains contingent on navigating the transition from temporary NTAP reimbursement to standard ESRD bundle integration.
- Investors should monitor the $30.0M goodwill balance and potential revenue volatility as the initial DefenCath launch phase matures into a volume-driven model.
Verdict Logic
the company demonstrates strong cash-generating capacity with a P/E TTM of 3.85, though investors should remain cautious regarding the sustainability of reimbursement-driven revenue streams.
CRMD Growth Metrics
CorMedix Inc. (CRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years107.55%
5 Years319.75%
3 Years1582.83%
TTM384.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM953.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM847.04%
Return on Capital
10 Years-102.43%
5 Years-34.18%
3 Years-21.82%
Last Year40.75%
CRMD Recent Earnings
CorMedix Inc. (CRMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (44%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.43+22.9%
$0.35
Rev
$127M+21.4%
$105M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.61-29.1%
$0.86
Rev
$129M+1.3%
$127M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.57+18.8%
$0.48
Rev
$104M-17.9%
$127M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.28+40.0%
$0.20
Rev
$40M-6.4%
$42M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.43vs $0.35+22.9% | $127Mvs $105M+21.4% |
| Q2 2026 | Mar 5, 2026 | $0.61vs $0.86-29.1% | $129Mvs $127M+1.3% |
| Q4 2025 | Nov 12, 2025 | $0.57vs $0.48+18.8% | $104Mvs $127M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.28vs $0.20+40.0% | $40Mvs $42M-6.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CorMedix Inc. (CRMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.87 | $695.87M | 4.35 | 617.03% | 52.31% | 66.56% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — |
Compare CRMD vs Peers
CorMedix Inc. (CRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRMD SEC Filings & Documents
CorMedix Inc. (CRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRMD Frequently Asked Questions
CorMedix Inc. (CRMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CorMedix Inc.'s revenue?
CorMedix Inc. (CRMD) reported $400.1M in revenue for fiscal year 2025.
How fast is CorMedix Inc. growing?
CorMedix Inc. (CRMD) grew revenue by 617.0% over the past year. This is strong growth.
Is CRMD profitable?
Yes, CorMedix Inc. (CRMD) is profitable, generating $181.0M in net income for fiscal year 2025 (52.3% net margin).
Dividend & Returns
What is CRMD's return on equity?
CorMedix Inc. (CRMD) has a return on equity (ROE) of 66.6%. This is excellent, indicating efficient use of shareholder capital.
What is CorMedix Inc.'s free cash flow?
CorMedix Inc. (CRMD) generated $196.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.